Quick Facts

Chemical Name
Glucagon-Like Peptide-1
Also Known As
Semaglutide, Liraglutide
Category
Metabolic & Weight Loss
Administration
Subcutaneous injection, typically once weekly

What is GLP-1 Agonists?

GLP-1 (Glucagon-Like Peptide-1) is a naturally occurring incretin hormone that regulates blood sugar and appetite. GLP-1 receptor agonists are synthetic peptides that mimic and enhance these effects. Medications in this class include semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro, Zepbound). These have become among the most prescribed medications for diabetes and obesity, with clinical trials showing unprecedented weight loss results.

How Does GLP-1 Agonists Work?

GLP-1 agonists bind to GLP-1 receptors in the pancreas, brain, and gut. In the pancreas, they stimulate insulin release and suppress glucagon in a glucose-dependent manner. In the brain, they act on appetite centers to reduce hunger and increase satiety. They also slow gastric emptying, contributing to reduced food intake. Newer versions are modified to resist degradation by DPP-4 enzyme, dramatically extending their half-life from minutes to days or weeks.

Research-Backed Benefits

Significant Weight Loss

Strong Evidence

Clinical trials show 15-20% body weight reduction with semaglutide, up to 25% with tirzepatide.

Blood Sugar Control

Strong Evidence

Highly effective for type 2 diabetes, reducing HbA1c by 1-2% typically.

Cardiovascular Protection

Strong Evidence

Demonstrated reduction in major cardiovascular events in multiple large trials.

Reduced Appetite

Strong Evidence

Substantially decreases hunger and food cravings through central and peripheral mechanisms.

Dosage Guidelines

Disclaimer: This content is for educational purposes only. Peptides are research compounds not approved by the FDA for human use. Always consult with a qualified healthcare provider.

Typical Range
Semaglutide: 0.25-2.4 mg/week; Tirzepatide: 2.5-15 mg/week
Frequency
Once weekly injection for most
Duration
Ongoing; weight regain common after discontinuation

Slow dose titration essential to minimize GI side effects. Start low and increase gradually.

Side Effects & Safety

  • Nausea (most common, usually improves)
  • Vomiting
  • Diarrhea or constipation
  • Potential gallbladder issues
  • Rare: pancreatitis
  • Theoretical: thyroid tumor risk (seen in rodents)
  • Muscle loss may accompany fat loss

Frequently Asked Questions

Clinical trials show average weight loss of 15-20% with semaglutide 2.4mg weekly and up to 25% with tirzepatide at highest doses. Individual results vary.
They have extensive safety data from diabetes use and multiple large cardiovascular outcome trials showing safety and benefit. Long-term weight maintenance use data is still being collected.
Studies show significant weight regain after discontinuation, suggesting these may need to be continued long-term to maintain results. Lifestyle changes during treatment are important.
Both contain semaglutide. Ozempic (max 2mg) is approved for diabetes; Wegovy (max 2.4mg) is approved specifically for weight loss. Wegovy reaches higher doses.

References

  1. Wilding JPH, et al. "STEP trial semaglutide weight loss." NEJM, 2021. PMID: 33567185
  2. Jastreboff AM, et al. "Tirzepatide SURMOUNT-1." NEJM, 2022. PMID: 35658024

Get the Complete GLP-1 Agonists Research Protocol

Join 50,000+ researchers with instant access to our comprehensive peptide resource.

Continue Your Research